Free Newsletter
Nanotech grows more common in drug dev research
Nanotechnology, including nanoscale drug delivery devices, is becoming steadily more common in the field of drug development and research. One example of this trend comes from Accelrys, which specializes in developing software for use in drug development work. Accelrys has enlisted some high-powered scientific help to broaden their level of expertise. MIT scientist Dr. Robert Langer has been brought in to provide additional insight into ways that software can be used to model new approaches in nanobiology. Article
More stories about nanotechnology
Paid Research Reports
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
- Optimizing Lifecycle Management: Maximizing commercial lifespan through label expansion and combination products
- The CRO Market Outlook: Emerging markets, leading players and future trends
- Pharmaceutical Sales Force Effectiveness Strategies
- Commercial Insight: Influenza Vaccines and Antivirals - The pandemic's long-term impact




